Carna Biosciences
Basic Information
- Stock Code
- 4572
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Hyogo Prefecture
- Establishment Year
- April 2003
- Listing Year
- March 2008
- Official Website
- https://www.carnabio.com/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- GNI Group, Heartseed, V Break Systems, Kaizen Platform, Nexela Pharma, Immuno-Biological Laboratories, De Western Therapeutics Institute, SymBio Pharmaceuticals, Kaiom Biosciences, Medorex, Peptidream, SanBio, Helios, BrightPath Bio, Delta-Fly Pharma, RenaScience, QualiPS, Takara Bio, PhoenixBio, Japan Tissue Engineering
Overview
Carna Biosciences is a bio-venture founded in 2003, one of Japan's leading pharmaceutical manufacturers that develops drug discovery support and proprietary drug development centered on kinase protein production.
Current Situation
Carna Biosciences recorded consolidated sales of approximately ¥750 million for the fiscal year ended December 2018, but is facing significant operating, ordinary, and net losses. It specializes mainly in drug discovery support through the manufacturing and sales of kinase enzymes, and has established a U.S. subsidiary to expand into the North American market. In 2019, it signed a major license agreement with Gilead Sciences on drug discovery technology, receiving an upfront payment of approximately ¥2.1 billion and a total valuation of approximately ¥50 billion. Technically, it focuses on new drug research using kinase core technology, demonstrating uniqueness in the bio-drug discovery field. Its stock is listed on the Tokyo Stock Exchange Growth section, and as an R&D-type venture, it is in the growth stage. Building a sustainable R&D framework and strengthening overseas expansion are key future themes, particularly aiming for market growth through expanded license agreements targeting the U.S. and China.
Trivia
Interesting Facts
- Bio-venture spun off from the research division of Japan Organon.
- Holds top-class domestic market share in kinase enzyme manufacturing.
- The 2019 contract with Gilead is an exceptionally large deal for a drug discovery venture.
- Established U.S. subsidiary and actively expanding overseas business.
- R&D company headquartered at Kobe Biomedical Innovation Cluster.
- Ono Pharmaceutical is one of its major shareholders.
- High-value-added company specialized in kinase target drug discovery research.
- Relatively young venture among listed pharmaceutical companies.
- Offers numerous specialized frequently used reagents under its own brands.
- License agreements include ¥2.1 billion upfront and total approximately ¥50 billion.
- Possesses high technological capabilities with around 60 employees.
- Pharmaceutical-related company aiming for growth on the TSE Growth market.
- Accelerating technology provision and joint research for overseas pharmaceutical companies.
- Maintains competitiveness with multiple patents utilizing proprietary technologies.
- Provides advanced drug discovery support services in addition to conventional pharmaceutical development.
Hidden Connections
- Jointly advancing new drug development through technology alliance with major shareholder Ono Pharmaceutical.
- Direct access to North American market via U.S. subsidiary CarnaBio USA.
- The 2019 Gilead Sciences contract is one of the largest for domestic drug discovery ventures.
- Actively engages in joint research with peer companies to promote technology exchange.
- Contributing to Kobe's bio-cluster formation as a regional hub company.
- Possesses global pharmaceutical development network through contracts with overseas pharmaceutical companies.
- Director stockholding association exists, linking to management stability and employee incentives.
- Compared to other ventures, has ample capital base of approximately ¥3.6 billion.
Future Outlook
Growth Drivers
- Expanding demand for kinase-related products in the global pharmaceutical market
- Technological innovations and service expansions supporting drug discovery efficiency
- Revenue base strengthening through increased overseas license agreements
- Acceleration of overseas expansion including Asian markets
- Diversification of targets in pharmaceutical development
Strategic Goals
- Achieve sales exceeding ¥2 billion
- Triple the number of overseas license agreements
- Expand global share of drug discovery support services
- Establish sustainable R&D framework
- Build drug discovery platform utilizing AI technology
Business Segments
Drug Discovery Support Services
- Overview
- Supports enhancement of pharmaceutical companies' R&D capabilities through drug discovery support services centered on kinase enzymes.
- Competitiveness
- High-purity enzyme supply and extensive drug discovery expertise
- Customers
-
- Pharmaceutical companies
- Bio ventures
- Universities and research institutions
- National research institutes
- Pharmaceutical development companies
- Pharmaceutical contract development organizations
- Chemical manufacturers
- Medical device companies
- Government research institutions
- CROs (contract research organizations)
- Products
-
- Kinase product supply
- Enzyme activity measurement contracts
- Compound screening
- Target analysis services
- Contract synthesis services
- Drug discovery consulting
- New drug design support
- Efficacy evaluation
- Protein engineering development
- Protein expression technology
New Drug Discovery Business
- Overview
- Challenging business field responding to medical needs through new drug development utilizing proprietary core technologies.
- Competitiveness
- Innovative kinase-related drug discovery technology
- Customers
-
- Medical institutions
- Clinical trial facilities
- Pharmaceutical partners
- Therapeutic drug producers
- Biopharma companies
- Products
-
- Kinase target drug discovery candidate compounds
- Pharmaceutical candidate compounds
- Therapeutic drug delivery technology
- Biopharmaceutical development
- Product commercialization preparation services
Overseas License Agreements Business
- Overview
- Business forming revenue base through large-scale license agreements with companies like Gilead.
- Competitiveness
- Strong partnerships with world-class pharmaceutical companies
- Customers
-
- U.S. pharmaceutical companies
- Chinese pharmaceutical companies
- Global pharmaceutical partners
- Products
-
- Licensing of pharmaceutical technologies
- Joint R&D agreements
- Technology transfer support
Technology Development and Research Contracts
- Overview
- Contributes to strengthening technology base by contracting various drug discovery-related research.
- Competitiveness
- Research expertise and technology integration capabilities
- Customers
-
- Academia
- Major pharmaceutical R&D departments
- Biotech companies
- Products
-
- Drug discovery research project contracts
- Technology validation services
- Drug discovery tool development
Product Sales and Marketing Support
- Overview
- Deploys marketing to enhance product market penetration and awareness.
- Competitiveness
- Sales capabilities backed by specialized knowledge
- Customers
-
- Specialized research institutions
- Drug discovery ventures
- Pharmaceutical sales agents
- Products
-
- Product distribution channel development
- Marketing materials provision
- Promotion planning support
Competitive Advantage
Strengths
- High-purity kinase enzyme production technology
- Extensive drug discovery support expertise
- License agreements with major pharmaceutical companies
- U.S. subsidiary for overseas expansion
- Proprietary kinase core technology
- Flexibility of R&D-type ventures
- Strong patent portfolio
- Advanced bio-manufacturing processes
- Outstanding corporate brand
- Specialized customer support
- Established sales channels domestically and internationally
- Well-equipped technical staff
- Continuous promotion of technological innovation
- Global partnerships
- Rapid product development cycle
Competitive Advantages
- Highly evaluated technical strength in pharmaceuticals
- Numerous joint research achievements with major pharmaceutical companies
- Wide lineup of kinase-related products
- Overseas market support leveraging U.S. subsidiary
- Provision of cutting-edge, high-precision research tools
- Services specialized in drug discovery support
- Successful differentiation from competitors through proprietary technology
- High revenue expectations from license agreements
- Flexible structure responding to market trends
- Leading position in research-use kinase enzyme field
- Product lineup adaptable to diverse industry needs
- Structure supporting entire drug discovery process
- High trust and brand power in the industry
- Utilization of global partnership network
- Sustainable growth through advanced technological development
Threats
- Intensifying competition among drug discovery ventures
- Strengthening of in-house research by major pharmaceutical companies
- Profit pressure from patent expirations
- Risks from overseas market regulatory tightening
- Unstable fundraising environment
- Burden from increasing R&D expenses
- Risks of technology leakage or imitation
- Potential delays in pharmaceutical development schedules
- Cost increases due to exchange rate fluctuations
- Risks of failure in new technology development
- Intensifying competition for major customers
- Impacts from external environmental changes such as infectious diseases
Innovations
2022: Major License Agreement with Gilead Sciences
- Overview
- Agreement signed on kinase-related therapeutic drug development using drug discovery technology
- Impact
- Upfront payment of approximately ¥2.1 billion secured, expecting total license income of approximately ¥50 billion
2020: License Agreement Signed with China's BioNova
- Overview
- Provision of drug discovery technology to Asian market and promotion of joint research
- Impact
- Establishment of business expansion base in Asia
2021: Improved High-Purity Purification Technology for Kinase Proteins
- Overview
- Manufacturing process improvement simultaneously achieving activity maintenance and stable supply
- Impact
- Improved product quality and 20% productivity increase
2023: Launch of New Enzyme Assay Kit for Drug Discovery
- Overview
- Development of new kit significantly improving screening efficiency
- Impact
- Improved customer satisfaction and increased new orders
2024: Research Started on Kinase Exploration Efficiency Using AI
- Overview
- Introduction of AI technology to accelerate next-generation drug discovery research
- Impact
- Expected shortening of new drug candidate discovery period
Sustainability
- Thorough cleanroom management for production environment
- Introduction of energy-saving manufacturing processes
- Waste reduction and recycling promotion
- Building sustainable supply chains
- Cooperation with local communities on environmental conservation
- Employee environmental awareness improvement and education
- Environmental burden reduction using bio-technology
- Compliance with ethical research guidelines
- Safety-first R&D operations
- Regular reporting of environmental performance
- Adoption of resource-saving packaging materials
- Ongoing efforts to reduce water usage